Literature DB >> 28592547

Performance of the Abbott RealTime MTB and MTB RIF/INH Assays in a Setting of High Tuberculosis and HIV Coinfection in South Africa.

Lesley Scott1, Anura David2,3, Lara Noble2, Matilda Nduna2, Pedro Da Silva3, Andrew Black4, Francois Venter4, Wendy Stevens2,3.   

Abstract

South Africa is a country with a high incidence of tuberculosis (TB), complicated by coinfection with human immunodeficiency virus (HIV). The Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) is used in South Africa as the test for the initial diagnosis of TB, and other molecular platforms such as the m2000 (Abbott Molecular, Des Plaines, IL, USA) are widely used for molecular monitoring of HIV load. The latter platform is now also equipped with the RealTime (RT) MTB and RealTime MTB RIF/INH assays for TB and first-line drug resistance screening but has not been evaluated in settings of HIV and TB coinfection. A prospective clinical validation study was conducted at a community health center in Johannesburg, South Africa, and consenting individuals with presumptive pulmonary TB were enrolled. The performance of the Abbott assays was compared with those of the Xpert MTB/RIF, liquid culture, drug susceptibility testing, and clinical case definitions. A statistical analysis was performed on 206 individuals (73% were HIV positive). The sensitivity and specificity of the RT MTB were 82.5% (confidence interval [CI], 67.2 to 92.7) and 93.1% (CI, 86.2 to 97.2) on raw sputum and 77.5% (CI, 61.5 to 89.2) and 95.1% (CI, 88.9 to 98.4) on concentrated sputum, respectively, compared with those from liquid culture. The RT MTB correctly identified 17/35 more smear-negative culture-positive specimens than the Xpert MTB/RIF. Both the RT MTB and the Xpert MTB/RIF displayed sensitivities >70% and specificities >90% in HIV-positive individuals. The available drug resistance results concurred with MTBDRplus and drug susceptibility profiles. The RT MTB assay has similar diagnostic performance to the Xpert MTB/RIF and is suited to testing presumptive TB patients coinfected with HIV. The existing laboratory information system connectivity, training, and technical support make this a viable polyvalent option to scale up TB alongside HIV laboratory testing services in South Africa.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Abbott RealTime MTB; South Africa; diagnostics; human immunodeficiency virus; tuberculosis

Mesh:

Year:  2017        PMID: 28592547      PMCID: PMC5527428          DOI: 10.1128/JCM.00289-17

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  MDR tuberculosis control: time to change the dogma?

Authors:  Annelies Van Rie; Robin M Warren
Journal:  Lancet Respir Med       Date:  2015-11-18       Impact factor: 30.700

2.  Performance of the new automated Abbott RealTime MTB assay for rapid detection of Mycobacterium tuberculosis complex in respiratory specimens.

Authors:  J H K Chen; K K K She; T-C Kwong; O-Y Wong; G K H Siu; C-C Leung; K-C Chang; C-M Tam; P-L Ho; V C C Cheng; K-Y Yuen; W-C Yam
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-06-13       Impact factor: 3.267

3.  The Abbott RealTime MTB assay and the Cepheid GeneXpert assay show comparable performance for the detection of Mycobacterium tuberculosis in sputum specimens.

Authors:  Sheng Fen Wang; Xi Chao Ou; Qiang Li; Hui Wen Zheng; Yu Feng Wang; Yan Lin Zhao
Journal:  Int J Infect Dis       Date:  2016-03-03       Impact factor: 3.623

4.  Global isoniazid resistance patterns in rifampin-resistant and rifampin-susceptible tuberculosis.

Authors:  S E Smith; E V Kurbatova; J S Cavanaugh; J P Cegielski
Journal:  Int J Tuberc Lung Dis       Date:  2012-02       Impact factor: 2.373

Review 5.  Diagnosis of opportunistic infections: HIV co-infections - tuberculosis.

Authors:  Lesley Scott; Pedro da Silva; Catharina C Boehme; Wendy Stevens; Christopher M Gilpin
Journal:  Curr Opin HIV AIDS       Date:  2017-03       Impact factor: 4.283

6.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

7.  Evaluation of Xpert HIV-1 Qual assay for resolution of HIV-1 infection in samples with negative or indeterminate Geenius HIV-1/2 results.

Authors:  Michal Michaeli; Marina Wax; Yael Gozlan; Aviya Rakovsky; Ella Mendelson; Orna Mor
Journal:  J Clin Virol       Date:  2015-12-29       Impact factor: 3.168

8.  Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study.

Authors:  Lesley E Scott; Kerrigan McCarthy; Natasha Gous; Matilda Nduna; Annelies Van Rie; Ian Sanne; Willem F Venter; Adrian Duse; Wendy Stevens
Journal:  PLoS Med       Date:  2011-07-26       Impact factor: 11.069

9.  Options to Expand HIV Viral Load Testing in South Africa: Evaluation of the GeneXpert® HIV-1 Viral Load Assay.

Authors:  Natasha Gous; Lesley Scott; Leigh Berrie; Wendy Stevens
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

10.  Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis.

Authors:  Emily A Kendall; Mariam O Fofana; David W Dowdy
Journal:  Lancet Respir Med       Date:  2015-11-18       Impact factor: 30.700

View more
  14 in total

1.  Performance of the Roche cobas MTB Assay for the Molecular Diagnosis of Pulmonary Tuberculosis in a High HIV Burden Setting.

Authors:  Lesley Scott; Anura David; Lyndel Govender; Jan Furrer; Modiehi Rakgokong; Ziyaad Waja; Neil Martinson; Gabriel Eisenberg; Elizabeth Marlowe; Wendy Stevens
Journal:  J Mol Diagn       Date:  2020-08-01       Impact factor: 5.568

2.  Xpert MTB/RIF and Xpert MTB/RIF Ultra for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  David J Horne; Mikashmi Kohli; Jerry S Zifodya; Ian Schiller; Nandini Dendukuri; Deanna Tollefson; Samuel G Schumacher; Eleanor A Ochodo; Madhukar Pai; Karen R Steingart
Journal:  Cochrane Database Syst Rev       Date:  2019-06-07

3.  Performance of a Highly Sensitive Mycobacterium tuberculosis Complex Real-Time PCR Assay for Diagnosis of Pulmonary Tuberculosis in a Low-Prevalence Setting: a Prospective Intervention Study.

Authors:  Víctor Vinuesa; Rafael Borrás; María Luisa Briones; María Ángeles Clari; Vicenta Cresencio; Estela Giménez; Carmen Muñoz; Rosa Oltra; Emilio Servera; Talia Scheelje; Carlos Tornero; David Navarro
Journal:  J Clin Microbiol       Date:  2018-04-25       Impact factor: 5.948

4.  A Benchtop Automated Sputum-to-Genotype System Using a Lab-on-a-Film Assembly for Detection of Multidrug-Resistant Mycobacterium tuberculosis.

Authors:  Alexander V Kukhtin; Ryan Norville; Arial Bueno; Peter Qu; Nicole Parrish; Megan Murray; Darrell P Chandler; Rebecca C Holmberg; Christopher G Cooney
Journal:  Anal Chem       Date:  2020-03-24       Impact factor: 6.986

5.  Performance of Xpert MTB/RIF, Xpert Ultra, and Abbott RealTime MTB for Diagnosis of Pulmonary Tuberculosis in a High-HIV-Burden Setting.

Authors:  Wendy Stevens; Lesley Scott; Rebecca H Berhanu; Anura David; Pedro da Silva; Kate Shearer; Ian Sanne
Journal:  J Clin Microbiol       Date:  2018-11-27       Impact factor: 5.948

6.  Comparative Analytical Evaluation of Four Centralized Platforms for the Detection of Mycobacterium tuberculosis Complex and Resistance to Rifampicin and Isoniazid.

Authors:  Margaretha de Vos; Lesley Scott; Anura David; Andre Trollip; Harald Hoffmann; Sophia Georghiou; Sergio Carmona; Morten Ruhwald; Wendy Stevens; Claudia M Denkinger; Samuel G Schumacher
Journal:  J Clin Microbiol       Date:  2021-02-18       Impact factor: 5.948

7.  Performance of the Abbott RealTime MTB and RIF/INH resistance assays for the detection of Mycobacterium Tuberculosis and resistance markers in sputum specimens.

Authors:  Bezalem Tesfaye Araya; Kirubel Eshetu Ali; Dereje Assefa Geleta; Saba Gebremichael Tekele; Kassu Desta Tulu
Journal:  PLoS One       Date:  2021-05-12       Impact factor: 3.240

8.  Evaluation of a new automated Abbott RealTime MTB RIF/INH assay for qualitative detection of rifampicin/isoniazid resistance in pulmonary and extra-pulmonary clinical samples of Mycobacterium tuberculosis.

Authors:  Pilar Ruiz; Manuel Causse; Manuel Vaquero; Juan Bautista Gutierrez; Manuel Casal
Journal:  Infect Drug Resist       Date:  2017-12-06       Impact factor: 4.003

9.  Performance of the Abbott RealTime MTB RIF/INH resistance assay when used to test Mycobacterium tuberculosis specimens from Bangladesh.

Authors:  Joshua Kostera; Gregor Leckie; Klara Abravaya; Hong Wang
Journal:  Infect Drug Resist       Date:  2018-05-11       Impact factor: 4.003

10.  The Performance of the Abbott Real Time MTB RIF/INH Compared to the MTBDRplus V2 for the Identification of MDR-TB Among Isolates.

Authors:  Anura David; Lyndel Singh; Pedro Da Silva; Lesley Scott; Wendy Stevens
Journal:  Infect Drug Resist       Date:  2020-09-28       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.